REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

31 May 2025 05:04:38 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

30 May 2025 06:45:02 By NetDania Notify

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

29 May 2025 22:00:00 By Nasdaq GlobeNewswire

Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

22 May 2025 14:00:13 By Nasdaq GlobeNewswire

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness

19 May 2025 04:07:52 By Nasdaq GlobeNewswire

75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition

16 May 2025 08:24:49 By Nasdaq GlobeNewswire

Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments

15 May 2025 11:02:43 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

08 May 2025 06:50:56 By NetDania Notify

Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination

01 May 2025 06:30:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases

01 May 2025 06:00:00 By Nasdaq GlobeNewswire

Regeneron Reports First Quarter 2025 Financial and Operating Results

29 Apr 2025 03:30:00 By Nasdaq GlobeNewswire

Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma

28 Apr 2025 04:01:41 By Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease

28 Apr 2025 04:00:32 By Nasdaq GlobeNewswire

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines

22 Apr 2025 03:00:00 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

21 Apr 2025 13:05:00 By Nasdaq GlobeNewswire

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

18 Apr 2025 12:00:22 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

18 Apr 2025 08:15:32 By Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications

17 Apr 2025 04:00:08 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

09 Apr 2025 06:45:11 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

08 Apr 2025 10:12:54 By NetDania Notify